DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,400 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices.
Summary for Tradename: ARGATROBAN
Clinical Trials for: ARGATROBAN
Randomized Controlled Trial of Argatroban With tPA for Acute Stroke
Status: Recruiting Condition: Ischemic Stroke
Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting
Status: Recruiting Condition: CVD
Argatroban Versus Lepirudin in Critically Ill Patients
Status: Terminated Condition: Heparin Induced Thrombocytopenia (HIT)
Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
Status: Completed Condition: Coronary Artery Disease; Angina, Unstable
Argatroban in Critically Ill Patients With Heparin Resistance
Status: Recruiting Condition: Achievement of a Sufficient Thrombosis Prohpylaxis in Clitically Ill Patients With Heparin Resistance
Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion
Status: Terminated Condition: Coronary Artery Bypass Graft Surgery; Presence of Heparin/Platelet Factor 4 Antibody
Argatroban TPA Stroke Study
Status: Completed Condition: Acute Ischemic Stroke
Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia
Status: Completed Condition: Heparin-Induced Thrombocytopenia
Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II
Status: Completed Condition: Heparin-induced Thrombocytopenia Type II
A Comparative Sudy Comparing ArgatrobanÂ® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome
Status: Terminated Condition: Suspected Heparin-Induced Thrombocytopenia
Courtesy of ClinicalTrials.org
See more clinical trials for this drug
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Product||Substance||Delist_Flag||Patent Expiration||Exclusivity Expiration|
|INJECTABLE; INJECTION||020883||Jun 30, 2000||RX||Yes||<disabled>||<disabled>|
|INJECTABLE; INJECTION||020883||Jun 30, 2000||RX||Yes||5,214,052||<disabled>||<disabled>|
|The preview shows a limited data set. Complete access is available with a Subscription|
Export unavailable in trial.
Subscribe for complete access.
|argatroban in sodium chloride||Injection||1 mg/mL, 50 mL vials||Argatroban||12/16/2011|
|argatroban||Injection||100 mg/mL, 2.5 mL vials||Argatroban||9/24/2007|
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639